ReviewJournal of molecular medicine (Berlin, Germany)2026
Tumor-intrinsic TLR4 signaling as a context-dependent rheostat in glioblastoma.
Review in Journal of molecular medicine (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) remains resistant to therapy due to cellular heterogeneity and adaptive stress responses, yet the role of tumor-intrinsic Toll-like receptor 4 (TLR4) signaling in this process remains unresolved. This review addresses a central inconsistency in the field by defining tumor-intrinsic TLR4 as a context-dependent signaling rheostat that generates distinct biological outcomes rather than a uniform tumor-promoting pathway. Across experimental systems, TLR4 signaling produces divergent effects that range from mesenchymal transition, invasion, and adaptive survival under chronic or therapy-associated conditions, to differentiation, apoptosis, and increased treatment sensitivity under specific cellular and temporal contexts. These opposing outputs are not contradictory but arise from defined determinants, including ligand environment, signaling dynamics, tumor cell state, and metabolic conditions. This framework explains previously discordant findings and establishes that the functional role of tumor-intrinsic TLR4 cannot be inferred from receptor activation alone. Instead, its impact is conditional and state-dependent. This perspective defines a clear experimental and translational priority: to identify the contexts in which tumor-intrinsic TLR4 signaling sustains tumor persistence versus exposes therapeutic vulnerability, thereby enabling rational and stratified intervention strategies in GBM.
Indexed as
Identifiers
42461375What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.